Silence Therapeutics (SLN) Short-Term Debt repayments (2020 - 2024)
Silence Therapeutics recorded quarterly Short-Term Debt repayments of -$63665.7 in Q3 2024, down 2.57% quarter-over-quarter from -$62067.6 in Q3 2023, and down 2.57% year-over-year from -$65348.3 in Q4 2023.
Silence Therapeutics' Short-Term Debt repayments history runs 5 years deep, the most recent figure standing at -$63665.7 for Q3 2024.
- In Q3 2024, Short-Term Debt repayments fell 2.57% year-over-year to -$63665.7; the TTM figure through Sep 2024 stood at -$226624.1 (down 25.46% YoY), while the FY2020 annual figure was -$516226.8, changed N/A from the prior year.
- Short-Term Debt repayments came in at -$63665.7 for Q3 2024 at Silence Therapeutics, down from -$62067.6 in the prior quarter.
- In the past five years, Short-Term Debt repayments ranged from a high of $559704.8 in Q3 2021 to a low of -$701659.6 in Q2 2021.
- A 5-year average of -$76467.7 and a median of -$62965.7 in 2022 frame the typical range for Short-Term Debt repayments.
- Across the five-year window, Short-Term Debt repayments soared 91.03% in 2022 and tumbled 251.1% in 2023, its largest moves.
- Silence Therapeutics' Short-Term Debt repayments stood at -$171658.6 in 2020, then jumped by 426.06% to $559704.8 in 2021, then plunged by 103.16% to -$17678.2 in 2022, then sank by 251.1% to -$62067.6 in 2023, then declined by 2.57% to -$63665.7 in 2024.
- According to Business Quant data, Short-Term Debt repayments over the past three periods registered -$63665.7, -$62067.6, and -$42546.3 for Q3 2024, Q3 2023, and Q2 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 102,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -63,665.71 |
| Sep 30, 2024 | -63,665.71 |
| Sep 30, 2023 | -62,067.55 |
| Sep 30, 2023 | -62,067.55 |
| Jun 30, 2023 | -42,546.35 |
| Jun 30, 2023 | -42,546.35 |
| Mar 31, 2023 | -58,344.46 |
| Mar 31, 2023 | -58,344.46 |
| Sep 30, 2022 | -17,678.22 |
| Sep 30, 2022 | -17,678.22 |
| Jun 30, 2022 | -62,965.71 |
| Jun 30, 2022 | -62,965.71 |
| Mar 31, 2022 | -63,066.28 |
| Mar 31, 2022 | -63,066.28 |
| Sep 30, 2021 | 559,704.84 |
| Sep 30, 2021 | 559,704.84 |
| Jun 30, 2021 | -701,659.58 |
| Jun 30, 2021 | -701,659.58 |
| Mar 31, 2021 | -157,196.97 |
| Mar 31, 2021 | -157,196.97 |
| Dec 31, 2020 | -171,658.63 |
| Dec 31, 2020 | -171,658.63 |